Transcriptional and proteomic insights into the immunomodulatory nature of SUPLEXA cells: An autologous cellular therapy for cancers

SUPLEXA cells show individualized cell subset profiles with common acquisition of tumor cytolytic and antigen presenting cell phenotypes.
Transcriptome analysis shows that cell killing, proliferation, and papain proteases are hub gene networks that are altered in SUPLEXA cells.
Baseline immune cell characteristics show striking differences with higher levels of NK cells and lower levels of MDSCs in patients showing clinical benefit.
Longitudinal CyTOF analysis PBMCs demonstrates pharmacodynamic increases in activated classical monocytes (SIGLEC-1+).
Analysis of longitudinal plasma samples reveal modulation of cytokines that impact inflammatory cytokine (IL-6) and hematopoietic factor (cKit) networks.